TechnoPhage, SA - From science to innovative biopharmaceuticals
Since the 1st January 2020, Technophage is a resident company of Johnson & Johnson Innovation, JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As…
COVID-19 New Challenge: joint effort to mitigate world’s pandemic crisis (TechnoPhage S.A., Faculty of Pharmacy of University of Lisbon and Vector B2B – Drug Developing Association for Research in Biotechnology) In Portugal, we have highly qualified human resources working in biological drug discovery and development. In a joint effort to tackle COVID-19 we…
COVID-19 patients suffering from severe forms of the disease are at risk of developing bacterial healthcare-associated infections, such as ventilator-associated pneumonia caused by multidrug resistant pathogens. TP-122 bacteriophage cocktail may be an alternative for such patients, because it consists of a biological therapeutic developed for the treatment of pneumonia caused by Pseudomonas aeruginosa,…